Compare Bristol-Myers Squibb Co (BMY) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs MGM Resorts International — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while MGM Resorts International trades at $46.89 (market cap $11.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.7× MGM Resorts International's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | MGM | |
|---|---|---|
Market Cap | $116.30B | $11.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $50.69 |
52-Week Low | $42.60 | $30.72 |
Enterprise Value | $152.24B | $40.98B |
Dividend Yield | 4.42% | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
MGM Resorts International (MGM) trades at $47.24, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $48.93. Recent financials show revenue growth to $17.54B in 2025, though net income margin remains thin at 1.03%. The stock is buoyed by acquisition talks with Barry Diller's People Inc. at $48.30 per share, as reported by The Wall Street Journal on July 10, 2026, and positive cash flow projections for 2026.
Outlook: MGM offers moderate upside potential driven by acquisition interest and steady revenue, but risks include volatile earnings, high debt, and regulatory scrutiny. Investors should weigh the takeover premium against fundamental weakness in profitability and execution risks in the competitive casino sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
